Scientific Publications
Newest First
All Years
Association Between Central Subfield Thickness Fluctuation and Visual Acuity Outcomes in Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Analysis of the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight)
The Retina Society Annual Meeting 2026
LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration: First-Time Safety and Treatment Burden Outcomes
The Retina Society Annual Meeting 2026
LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration: First-Time Vision and Anatomic Outcomes
The Retina Society Annual Meeting 2026
Bioerodible EYP-1901 (vorolanib intravitreal insert) for Sustained Release of a Tyrosine Kinase Inhibitor for Retinal Exudative Disease
The Retina Society Annual Meeting 2026
Bioerodible EYP-1901 (vorolanib intravitreal insert): Key Learnings from the Phase 2 DAVIO 2 Clinical Trial in Wet AMD
Women in Ophthalmology Summer Symposium 2026
Multi-Mechanism of Action of EYP-1901 in Retinal Exudative Diseases: Inhibition of IL-6 Signaling, VEGFR and PDGFR by Vorolanib
American Society of Retina Specialists (ASRS)
EYP-1901 for Wet Age-Related Macular Degeneration: Key Learnings from DAVIO 2 and the Clinical Trial Program
American Society of Retina Specialists (ASRS)
Bioerodible EYP-1901 (vorolanib intravitreal insert) for Diabetic Macular Edema: From the Phase 2 VERONA Trial to Pivotal Phase 3 Program
American Society of Retina Specialists (ASRS)
DAVIO 2 Phase 2 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) for Wet AMD: Post Hoc Analysis in Patients who met Phase 3 Criteria
American Society of Retina Specialists (ASRS)
Update on EYP-1901 Clinical Trials in nAMD and DME
Clinical Trials at the Summit